Johnson & Johnson (JNJ) Receives Adverse Ruling in REMICADE Patent Litigation – StreetInsider.com

Johnson & Johnson (JNJ) Receives Adverse Ruling in REMICADE Patent Litigation
StreetInsider.com
The court issued a ruling in favor of Celltrion and Hospira, holding that U.S. Patent No. 6,284,471 for REMICADE® ('471 patent) is invalid. Janssen is disappointed with the court's ruling and plans to appeal the decision to the Court of Appeals for the

and more »

Leave a Reply

Your email address will not be published. Required fields are marked *